We are live on ! Find out more
ARNA

Arena Pharmaceuticals Inc

Delisted

ARNA was delisted on the 10th of March, 2022.

129 hedge funds and large institutions have $401M invested in Arena Pharmaceuticals Inc in 2014 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 42 increasing their positions, 37 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 14

14% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 37

7% more funds holding

Funds holding: 121129 (+8)

11% less capital invested

Capital invested by funds: $451M → $401M (-$50.3M)

46% less call options, than puts

Call options by funds: $10.8M | Put options by funds: $19.8M

Holders
129
Holders Change
+8
Holders Change %
+6.61%
% of All Funds
3.44%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
24
Increased
42
Reduced
37
Closed
14
Calls
$10.8M
Puts
$19.8M
Net Calls
-$9.03M
Net Calls Change
+$3.61M
Name Holding Trade Value Shares
Change
Change in
Stake
BG
51
BlackRock Group
United Kingdom
$512K +$237K +5,835 +65%
SCM
52
Stevens Capital Management
Pennsylvania
$509K +$522K +12,856 +709%
VOYA Investment Management
53
VOYA Investment Management
Georgia
$478K
AQR Capital Management
54
AQR Capital Management
Connecticut
$426K -$3.65K -90 -0.7%
BA
55
BlackRock Advisors
Delaware
$422K -$22.2K -548 -4%
DekaBank Deutsche Girozentrale
56
DekaBank Deutsche Girozentrale
Germany
$401K -$42.6K -1,050 -8%
SG Americas Securities
57
SG Americas Securities
New York
$401K +$324K +7,989 +224%
Nomura Holdings
58
Nomura Holdings
Japan
$394K +$129K +3,187 +42%
PP
59
PDT Partners
New York
$393K
Janney Montgomery Scott
60
Janney Montgomery Scott
Pennsylvania
$389K +$4.06K +100 +0.9%
NPC
61
National Planning Corporation
California
$361K -$47.7K -1,175 -16%
Deutsche Bank
62
Deutsche Bank
Germany
$353K -$2.03M -50,055 -83%
SIM
63
Spark Investment Management
New York
$337K +$396K +9,750 New
UBS AM
64
UBS AM
Illinois
$323K +$35.3K +870 +10%
Citigroup
65
Citigroup
New York
$317K +$327K +8,062 +763%
T. Rowe Price Associates
66
T. Rowe Price Associates
Maryland
$274K +$67K +1,650 +26%
Bank of America
67
Bank of America
North Carolina
$273K -$72.3K -1,782 -18%
ST
68
Spot Trading
Illinois
$258K +$302K +7,430 New
MP
69
Mangrove Partners
Connecticut
$247K -$567K -13,970 -66%
UBS Group
70
UBS Group
Switzerland
$220K +$257K +6,330 New
LPL Financial
71
LPL Financial
California
$217K -$73.7K -1,815 -22%
NIT
72
NumerixS Investment Technologies
British Columbia, Canada
$215K +$252K +6,197 New
LWM
73
Lyons Wealth Management
Florida
$196K
CSS
74
Cubist Systematic Strategies
Connecticut
$191K +$223K +5,490 New
AG
75
Aperio Group
California
$171K +$1.42K +35 +0.7%

ARNA Hedge Fund Activity: Q4 2014 in Review

129 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q4 2014, worth a combined $401M — down 11% from $451M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ARNA positions and 14 closed out — a net gain of 10 holders — while 42 added to existing stakes and 37 trimmed.

The largest buyer was Millennium Management, adding an estimated $6.56M. The largest seller was Guggenheim Capital, cutting an estimated $3.02M.

  • 129 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q4 2014, up from 121 in Q3 2014.
  • Funds reported $401M of Arena Pharmaceuticals Inc stock for Q4 2014, down 11% quarter-over-quarter.
  • 24 funds opened new Arena Pharmaceuticals Inc positions in Q4 2014 and 14 closed out, a net change of +10 holders.
  • The largest Arena Pharmaceuticals Inc buyer in Q4 2014 was Millennium Management, an estimated $6.56M added.
  • The largest Arena Pharmaceuticals Inc seller in Q4 2014 was Guggenheim Capital, an estimated $3.02M sold.

Based on aggregated 13F filings for Q4 2014.